Organization (Industry)
HAEMONETICS CORPORATION
ClinicalTrials.gov lists HAEMONETICS CORPORATION as lead sponsor of 28 trials, counting the companies grouped under it. HAEMONETICS CORPORATION itself has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo MelanieCommunications, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers HAEMONETICS CORPORATION and 3 companies grouped under it: 28 lead-sponsored trials (11 its own, 17 in the grouped companies) and 7 legal-entity registrations (5 its own, 2 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Vivasure Medical Limited (Ireland) | 11 | 1 |
| Cardiva Medical, Inc. | 6 | 0 |
| HAEMONETICS MANUFACTURING, INC. | 0 | 1 |
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hemorrhage | 3 |
| Thrombosis | 3 |
| Adenocarcinoma of Lung | 1 |
| Atherosclerosis | 1 |
| Atrial Fibrillation | 1 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 1 |
| 2012 | 3 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| 0,9% Chloride Sodium | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | 1 of 1 on time (n=1) |
Journals published in (11)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of trauma | 5 |
| Journal of vascular surgery | 3 |
| Anesthesiology | 1 |
| Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis | 1 |
| British journal of anaesthesia | 1 |
Showing 5 of 11 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 165 | 26 | 2025-10-07 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | 1,334,027,000 | 97,308,000 | 59,766,000 |
| 2025 | 1,360,824,000 | 167,679,000 | 62,722,000 |
| 2024 | 1,309,055,000 | 117,558,000 | 54,435,000 |
| 2023 | 1,168,660,000 | 115,401,000 | 50,131,000 |
| 2022 | 993,196,000 | 43,375,000 | 46,801,000 |
| 2021 | not reported | 79,469,000 | 32,857,000 |
| 2020 | not reported | 76,526,000 | 30,883,000 |
| 2019 | not reported | 55,019,000 | 35,714,000 |
| 2018 | not reported | 45,572,000 | 39,228,000 |
| 2017 | not reported | -26,268,000 | 37,556,000 |
Showing 10 of 12 fiscal years.
Financing and grant events (29)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-02 | Debt financing | not disclosed | Sec extracted |
| 2026-01-09 | Other financing | not disclosed | Sec extracted |
| 2025-01-13 | Other financing | 45,300,000 | Sec extracted |
| 2024-12-03 | Other financing | not disclosed | Sec extracted |
| 2024-12-03 | Other financing | not disclosed | Sec extracted |
Showing 5 of 29 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 12 |
FDA recalls (31)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| TEG 5000 Functional Fibrinogen Reagent, Item No. 07-034 | Class II | 2022-04-26 |
| Product Name: TEG5000 Analyzer (07-022, 07-033) with TEG Analytical Software (07-030, 07-031) and TEG Platelet Mapping Assay - PlateletMapping ADP & AA (07-014), PlateletMapping ADP (07-015), PlateletMapping AA (07-016). Issue occurs when Platelet Mapping Assay results from a TEG 5000 analyzer are viewed using TEG Manager Software (versions 1.1-4.3.1) | Class II | 2022-04-19 |
| TEG Manager software versions used in conjunction with TEG 5000 are 1.1.0, 3.0.0, 4.0.0, 4.1.0 and 4.1.1. Intended: For in vitro coagulation studies | Class II | 2020-02-19 |
| CS5/5+ Fastpacks, 225 mL, 150¿ Res Autotransfusion Device - Product Usage: its related accessory components are intended to be used for the recovery and processing of blood shed during or subsequent to an operation or as a result of trauma. | Class II | 2019-10-21 |
| CS5/5+ Bowl Kit-125 mL Autotransfusion Device - Product Usage: its related accessory components are intended to be used for the recovery and processing of blood shed during or subsequent to an operation or as a result of trauma. | Class II | 2019-10-21 |
Showing 5 of 31 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2026-02-02 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| HAEMONETICS CORPORATION | Boston, US | FDA | |
| Haemonetics Corporation | Salt Lake City, US | FDA | |
| Haemonetics Corporation | Clinton, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2026 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2026 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Colorado System | Co sponsors trial with | 1 |
| The University of Texas System | Co sponsors trial with | 1 |
| Denver Health and Hospital Authority | Co sponsors trial with | 1 |
Latest dated events (261)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-02 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-02 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-01-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-09 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 261 events.
Biomarker capability evidence (17)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| TKTL1 | Trial collaborator | Named in trial inclusion criteria |
| EPO | Trial collaborator | Named in trial exclusion criteria |
| F2 | Trial collaborator | Named in trial exclusion criteria |
| GPT | Trial collaborator | Named in trial exclusion criteria |
| PLAT | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 17 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.